Clinical Trials Publications
Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma. Clin Genitourin Cancer 2014;12:130-137.
Authors: Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN(01), Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G.
First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer 2014;12:335-40. PMCID: PMC4164603
Authors: Harshman LC, Kroeger N, Rha SY, Donskov F, Wood L, Tantravahi SK, Vaishampayan U(01), Rini BI, Knox J, North S, Ernst S, Yuasa T, Srinivas S, Pal S, Heng DY, Choueiri TK
Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol 2014;epub. PMCID: PMC4051566
Authors: Heng DY, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T, Srinivas S, Donskov F, Bamias A, Wood LA, Ernst DS, Agarwal N, Vaishampayan UN(01), Rha SY, Kim JJ, Choueiri TK.
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer 2014;epub.
Authors: Hussain M, Daignault S, Agarwal N, Grivas PD, Siefker-Radtke AO, Puzanov I, Macvicar GR, Levine EG, Srinivas S, Twardowski P, Eisenberger MA, Quinn DI, Vaishampayan UN(01), Yu EY, Dawsey S, Day KC, Day ML, Al-Hawary M, Smith DC.
Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population. Clin Genitourin Cancer 2014;12:354-8. PMCID: PMC4156559
Authors: Khambati HK, Choueiri TK, Kollmannsberger CK, North S, Bjarnason GA, Vaishampayan UN(01), Wood L, Knox JJ, Tan MH, Mackenzie MJ, Donskov F, Rini BI, Heng DY.
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Br J Cancer 2014;110:1917-22. PMCID: PMC3992507
Authors: Ko JJ, Choueiri TK, Rini BI, Lee JL, Kroeger N, Srinivas S, Harshman LC, Knox JJ, Bjarnason GA, Mackenzie MJ, Wood L, Vaishampayan UN(01), Agarwal N, Pal SK, Tan MH, Rha SY, Yuasa T, Donskov F, Bamias A, Heng DY.
Bone-induced c-kit expression in prostate cancer: a driver of intraosseous tumor growth. Int J Cancer 2014;0
Authors: Mainetti LE, Zhe X, Diedrich J, Saliganan AD, Cho WJ, Cher ML(01), Heath E(03), Fridman R(01), Kim HR(01), Bonfil RD(01).
Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy. Eur Urol 2014;65:577-84. PMCID: PMC4123121
Authors: McKay RR, Kroeger N, Xie W, Lee JL, Knox JJ, Bjarnason GA, Mackenzie MJ, Wood L, Srinivas S, Vaishampayan UN(01), Rha SY, Pal SK, Donskov F, Tantravahi SK, Rini BI, Heng DY, Choueiri TK.
Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T. Expert Rev Anticancer Ther 2014;14:51-61.
Authors: Quinn DI, Vaishampayan U(01), Higano CS, Lin DW, Shore ND, Beer TM.
The effect of targeted therapy on overall survival in advanced renal cancer: a study of the national surveillance epidemiology and end results registry database. Clin Genitourin Cancer 2014;12:124-129. NIHMSID: NIHMS541093
Authors: Vaishampayan U(01), Vankayala H, Vigneau FD(04), Quarshie W, Dickow B, Chalasani S, Schwartz K(04).
Development of cabozantinib for the treatment of prostate cancer. Core Evid 2014;9:61-67. PMCID: PMC4003147
Author: Vaishampayan UN(01).
Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer. Urol Oncol 2014;32:e25-31. PMCID: PMC3872261
Authors: Vaishampayan UN(01), Fontana J(01), Heilbrun LK(03), Smith D, Heath E(03), Dickow B, Figg WD.